Volume 388, Issue 10058, Pages 2355-2365 (November 2016) Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial  Jyh-Ming Liou, MD, Yu-Jen Fang, MD, Chieh-Chang Chen, MD, Ming-Jong Bair, MD, Chi-Yang Chang, MD, Prof Yi-Chia Lee, MD, Mei- Jyh Chen, MD, Chien-Chuan Chen, MD, Cheng-Hao Tseng, MD, Yao-Chun Hsu, MD, Ji-Yuh Lee, MD, Tsung-Hua Yang, MD, Prof Jiing- Chyuan Luo, MD, Chun-Chao Chang, MD, Chi-Yi Chen, MD, Po-Yueh Chen, MD, Prof Chia-Tung Shun, MD, Wen-Feng Hsu, MD, Wen- Hao Hu, MD, Yen-Nien Chen, MD, Prof Bor-Shyang Sheu, MD, Prof Jaw-Town Lin, MD, Jeng-Yih Wu, MD, Prof Emad M El-Omar, MD, Prof Ming-Shiang Wu, MD  The Lancet  Volume 388, Issue 10058, Pages 2355-2365 (November 2016) DOI: 10.1016/S0140-6736(16)31409-X Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet 2016 388, 2355-2365DOI: (10.1016/S0140-6736(16)31409-X) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 2 Efficacies of first-line and second-line anti-Helicobacter pylori treatments T14=triple therapy for 14 days. C10=concomitant therapy for 10 days. BQ10=bismuth quadruple therapy for 10 days. The Lancet 2016 388, 2355-2365DOI: (10.1016/S0140-6736(16)31409-X) Copyright © 2016 Elsevier Ltd Terms and Conditions